Gliosarcoma drugs in development, 2023
The Gliosarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Gliosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gliosarcoma. Buy the report here.The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued products.GlobalData tracks 49 drugs in development for Gliosarcoma by 39 companies/universities/institutes. The top development phase for Gliosarcoma is phase i with 22 drugs in that stage. The Gliosarcoma pipeline has 43 drugs in development by companies and six by universities/ institutes. Some of the companies in the Gliosarcoma pipeline products market are: Bristol-Myers Squibb, Merck and ImmunityBio.The key targets in the Gliosarcoma pipeline products market include Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1), Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1), and Platelet Derived Growth Factor Receptor Beta (Beta Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member B or Platelet Derived Growth Factor Receptor 1 or CD140b or PDGFRB or EC 2.7.10.1).The key mechanisms of action in the Gliosarcoma pipeline product include Platelet Derived Growth Factor Receptor Beta (Beta Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member B or Platelet Derived Growth Factor Receptor 1 or CD140b or PDGFRB or EC 2.7.10.1) Inhibitor with three drugs in Phase III. The Gliosarcoma pipeline products include 15 routes of administration with the top ROA being Intravenous and ten key molecule types in the Gliosarcoma pipeline products market including Small Molecule, and Monoclonal Antibody.Gliosarcoma overviewGliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Common symptoms are headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.For a complete picture of Gliosarcoma's pipeline drug market, buy the report here.
GlobalData tracks 49 drugs in development for Gliosarcoma by 39 companies/universities/institutes. The top development phase for Gliosarcoma is phase i, with 22 drugs in that stage.
What's Your Reaction?
